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The abstract of this work was presented as an oral presentation at the Stroke Society of Australasia Conference, August 23 to 25, 2017, in Queenstown, New Zealand, and as a poster presentation at the Australian Diabetes Society Conference, August 30 to September 1, 2017, in Perth, Australia.

Clinical PerspectiveWhat Is New?Using a meta‐analytical approach, we found that higher glycated hemoglobin levels were associated with an increased risk of first‐ever ischemic stroke in both non--diabetes mellitus and diabetes mellitus cohorts.In people with established diabetes mellitus, higher glycated hemoglobin levels were associated with an increased risk of first‐ever stroke.What Are the Clinical Implications?Further interventional studies are needed to examine the effectiveness of more intensive glycemic control targets as part of primary and secondary stroke prevention, in pre--diabetes mellitus and diabetes mellitus cohorts.

Introduction {#jah33175-sec-0008}
============

Strokes represent a heterogeneous group of vascular pathologies that collectively act as a major global burden of mortality and lifelong morbidity. Diabetes mellitus is a major risk factor for the development of stroke, particularly ischemic stroke, with type 2 diabetes mellitus alone known to increase stroke risk 1.5 to 4 fold.[1](#jah33175-bib-0001){ref-type="ref"} Macrovascular complications of diabetes mellitus (ischemic heart disease (IHD), stroke, and peripheral vascular disease) represent a major cause of diabetes mellitus related mortality and health‐related expenditure.[2](#jah33175-bib-0002){ref-type="ref"}, [3](#jah33175-bib-0003){ref-type="ref"}

Glycated hemoglobin (HbA~1c~) is a validated marker of 2 to 3 month glycemic control used within routine diabetes mellitus care. Current American Diabetes Association (ADA) diabetes mellitus management guidelines recommend a base target of HbA~1c~ \<7.0% within routine diabetes mellitus care of non‐pregnant adults.[4](#jah33175-bib-0004){ref-type="ref"} This target is most validated for microvascular complication risk reduction and has unclear implications for optimal macrovascular risk reductions. Long‐term follow‐up studies of 2 randomized controlled trials (RCTs) have demonstrated beneficial effects on long‐term macrovascular outcomes with more intensive glycemic control, thereby suggesting a metabolic memory effect for hyperglycemia.[5](#jah33175-bib-0005){ref-type="ref"}, [6](#jah33175-bib-0006){ref-type="ref"}

Up to one half of all patients presenting with acute stroke have previously unknown abnormalities of glucose tolerance, with 20% to 40% of patients presenting with hyperglycemia at hospital admission.[7](#jah33175-bib-0007){ref-type="ref"} Chronic hyperglycemia has been linked with several stroke risk factors including accelerated atherosclerosis, increased carotid intima media thickness (CIMT), cardiomyocyte dysfunction, atrial fibrillation (AF), and ischemic heart disease.[8](#jah33175-bib-0008){ref-type="ref"}, [9](#jah33175-bib-0009){ref-type="ref"}, [10](#jah33175-bib-0010){ref-type="ref"}, [11](#jah33175-bib-0011){ref-type="ref"} In non--diabetes mellitus patients with insulin resistance and recent ischemic stroke or transient ischemic attack, long‐term treatment with pioglitazone reduced the risk of adverse cardiovascular outcomes.[12](#jah33175-bib-0012){ref-type="ref"} The outcomes of this trial suggested that in the ischemic stroke subgroup, anti‐hyperglycemic medication may need to start at lower HbA~1c~ thresholds than currently accepted levels.[12](#jah33175-bib-0012){ref-type="ref"}

No systematic review and meta‐analysis has generated consensus regarding the specific relationship between rising HbA~1c~ level and stroke risk.[13](#jah33175-bib-0013){ref-type="ref"}, [14](#jah33175-bib-0014){ref-type="ref"} We therefore aimed to fill this knowledge gap by conducting a systematic review and meta‐analysis of observational studies to examine and determine a quantifiable risk relationship for the association between rising HbA~1c~ level and stroke risk, stratified by diabetes mellitus status, stroke temporality, and stroke subtype.

Methods {#jah33175-sec-0009}
=======

Study Design and Registration {#jah33175-sec-0010}
-----------------------------

We systematically reviewed cohort and nested case‐control cohort studies that assessed the association between varying HbA~1c~ level and stroke risk. The protocol implemented as part of this systematic review and meta‐analysis was constructed using the combined recommendations of the Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA),[15](#jah33175-bib-0015){ref-type="ref"} Meta‐analysis of Observational Studies in Epidemiology (MOOSE) group,[16](#jah33175-bib-0016){ref-type="ref"} and the Cochrane Handbook for Systematic Reviews.[17](#jah33175-bib-0017){ref-type="ref"} This study is registered with PROSPERO (CRD42017056706). The data, analytic methods, and study materials will be/have been made available to other researchers for purposes of reproducing the results or replicating the procedure. These are available within this manuscript and the associated online data supplement.

Literature Search Strategy {#jah33175-sec-0011}
--------------------------

A systematic search of 5 literary databases (MEDLINE, Embase, PubMed, Web of Science, and the Cochrane Library) was performed between February 7, 2017, and March 5, 2017. Medical Subject Headings (MeSH) terms selected were synonymous with the following text words used: *glycosylated h(a)emoglobin, HbA* ~*1c*~ *, glycated h(a)emoglobin, stroke, cerebral infarction, cerebral h(a)emorrhage,* and *transient isch(a)emic attack*." MeSH terms were "exploded" to maximise coverage.

Search results were restricted to human (≥18 years old) and English only articles. No publication filters were applied within any database. Search results were managed and duplicate entries removed using EndNote X7.7.1. A manual search of study references was performed for completeness. A complete list of MeSH and text words with Boolean operators applied within MEDLINE are provided in Figure [S1](#jah33175-sup-0001){ref-type="supplementary-material"}.

Inclusion and Exclusion Criteria {#jah33175-sec-0012}
--------------------------------

Studies were considered for inclusion within meta‐analyses and sensitivity analyses performed if they met the following criteria: (1) presented adjusted hazard ratios (HRs) or risk ratios (RRs, relative risk) for the association between varying HbA~1c~ level and stroke risk, defined by temporality (first‐ever or recurrent) and subtype of event (ischemic, hemorrhagic, other); and (2) involved a minimum follow‐up period of ≥12 months.

We excluded studies that met any of the following criteria: (1) failed the automatic exclusion criteria within the Scottish Intercollegiate Guidelines Network (SIGN)^18^ quality tool (Data [S1](#jah33175-sup-0001){ref-type="supplementary-material"}); (2) focused on specific subpopulations (including end‐stage kidney disease (ESKD), dialysis, post‐thrombolysis (tPA), post‐myocardial infarction (AMI), and post‐operative cohorts); (3) had insufficient or missing data for extrapolation and quality assessment; and (4) compared diabetes mellitus to non--diabetes mellitus cohorts.

In the source literature, effect sizes (HR or RR) were variably adjusted for covariates, with multiple effect sizes often reported. Consequently, we extracted the most extensively covariate‐adjusted HR or RR data for use in the meta‐analysis. However, if in the original source article adjustment was performed for hypoglycemic medication use, we only included data that were not adjusted for hypoglycemic medication use, as the medication may have biased the association between the exposure and outcome. Data [S2](#jah33175-sup-0001){ref-type="supplementary-material"} provides a full description of inclusion and exclusion criteria applied during each phase of the search strategy.

Search Protocol Implementation and Data Extraction {#jah33175-sec-0013}
--------------------------------------------------

Two reviewers (J.P.M., G.P.M.) independently screened all available articles by title and abstract using predefined inclusion and exclusion criteria. Following this, 2 reviewers (J.P.M., V.T.) performed a full‐text review of articles identified through screening using predefined inclusion and exclusion criteria. Objective methodological study quality assessment was performed during full‐text review using 2 critical appraisal checklists for cohort studies.[18](#jah33175-bib-0018){ref-type="ref"}, [19](#jah33175-bib-0019){ref-type="ref"} Any disagreements were resolved through discussion between reviewers. Narrative synthesis was performed for all studies deemed suitable for inclusion in the meta‐analysis (n=36 studies). Data on key study parameters, including; author(s), year of publication, study location, sample size, participant demography, stroke outcome type, effect size data, and covariate adjustment performed, were extracted in duplicate and are detailed in Tables [S1](#jah33175-sup-0001){ref-type="supplementary-material"} through [S6](#jah33175-sup-0001){ref-type="supplementary-material"}. Any discrepancies in data extracted were resolved through consultation between authors.

Statistical Analyses and Bias Assessment {#jah33175-sec-0014}
----------------------------------------

The primary outcome measure of interest was the association between rising categorical or 1% increment (or equivalent) HbA~1c~ levels and stroke risk, stratified by diabetes mellitus status, stroke temporality, and stroke subtype. A random‐effects model was used for all meta‐analyses and sensitivity analyses. Meta‐analyses were only performed on strata that contained a minimum of 3 studies (n≥3) to ensure adequate analytical power. RR data were treated as equivalent to HR data in all analyses.

The association between rising categorical HbA~1c~ levels and first‐ever stroke risk was assessed through comparison of stroke risk between American Diabetes Association--defined non--diabetes mellitus range HbA~1c~ (\<5.7%) (reference category) to pre--diabetes mellitus range HbA~1c~ (5.7%--6.5%) and diabetes mellitus range HbA~1c~ (≥6.5%) categories. Only studies that used a reference category within non--diabetes mellitus range HbA~1c~ and at least 1 comparator category within pre--diabetes mellitus range or diabetes mellitus range HbA~1c~ were included (Data [S3](#jah33175-sup-0001){ref-type="supplementary-material"}, Figures [S2](#jah33175-sup-0001){ref-type="supplementary-material"} and [S3](#jah33175-sup-0001){ref-type="supplementary-material"}).

The association between 1% increments (or equivalent) of HbA~1c~ and first‐ever stroke risk was examined. Studies reporting 1 standard deviation (1sd) increment effect sizes were treated as equivalent to 1% HbA~1c~, as the magnitude of these 1 standard deviation increments ≈ 1% increments (1±0.4%) and the effect sizes quoted approximated the estimated 1% increment equivalents (Tables [S1-- S6](#jah33175-sup-0001){ref-type="supplementary-material"}).

Many studies only reported categorical data. A linear regression model was used to estimate natural log‐transformed 1% increment effect sizes and 95% confidence interval (CI) from this pool of categorical data using a method described by Greenland,[20](#jah33175-bib-0020){ref-type="ref"} with statistical significance set at *P*\<0.05. This estimated 1% data were then used within separate random‐effects model meta‐analyses performed. A detailed description of this method is provided in Data [S4](#jah33175-sup-0001){ref-type="supplementary-material"}, Figures [S4](#jah33175-sup-0001){ref-type="supplementary-material"} and [S5](#jah33175-sup-0001){ref-type="supplementary-material"}.

To avoid duplicate data use, whenever 2 studies reported on the same study population, we used the most recent study for the subgroup meta‐analysis performed. Baseline and time‐update mean values of HbA~1c~ were treated as equivalents. Time‐updated HbA~1c~ values were selected in preference to single baseline values in studies that presented both. A random‐effects model was used to generate overall effect sizes from effect size data that had been stratified by variables like sex or ethnicity.

Definitions used to classify stroke and diabetes mellitus status varied greatly within the source literature. Diabetes mellitus status was defined using reported diabetes mellitus status (medical history, clinician or patient reported) and/or glucose or HbA~1c~ measurement at study inclusion. Strokes were classified using *International Classification of Diseases,Ninth/Tenth Revision* (*ICD‐9/10*) codes, World Health Organization criteria and/or study‐defined stroke criteria. Stroke event occurrence was identified using hospital admission diagnosis, death certificate details, medical history details, clinician reports, and/or patient‐reported status.

Given the heterogeneity in diabetes mellitus and stroke outcome classification and reporting, the decision was made to assign both diabetes mellitus and stroke outcome status based on each study\'s reported outcome status. Effect sizes adjusted for diabetes mellitus status were treated as representing non--diabetes mellitus data. Effect sizes adjusted for past stroke history were treated as representing first‐ever stroke data.

Several sensitivity analyses were performed within this study, examining the; (1) effect of combining type 1 and type 2 diabetes mellitus cohorts, (2) importance of ischemic subtype stratification, (3) difference between estimated and quoted 1% HbA~1c~ increment data, and (4) effect of varying levels of covariate adjustment on results obtained. These sensitivity analyses are presented in Figures [S6](#jah33175-sup-0001){ref-type="supplementary-material"} through [S10](#jah33175-sup-0001){ref-type="supplementary-material"}. The linear‐regression estimated 1% HbA~1c~ meta‐analyses are presented in Figure [S11](#jah33175-sup-0001){ref-type="supplementary-material"}.

Based on the recommendations of the Cochrane Handbook,[17](#jah33175-bib-0017){ref-type="ref"} we did not perform formal meta‐regression because of insufficient study number (n\<10 studies per subgroup). We assessed for statistical heterogeneity using the I^2^ statistic. As per Higgins et al,[21](#jah33175-bib-0021){ref-type="ref"} we assigned adjectives of "low," "moderate," and "high" for I^2^ statistic values of 25%, 50% and 75%, respectively. I^2^ statistic values below 25% were assigned the adjective of "low." The I^2^ statistic describes the percentage of variation across studies that is attributable to heterogeneity rather than chance.[21](#jah33175-bib-0021){ref-type="ref"} Consequently, the categories of I^2^ statistic magnitude outlined do not refer to the absolute amount of observed heterogeneity.

Publication bias was assessed through construction of funnel plots and performing Egger\'s test for funnel plot asymmetry for each meta‐analysis performed ([Figures S12--S16](#jah33175-sup-0001){ref-type="supplementary-material"}). Statistical significance for publication bias assessment using Egger\'s test was set at *P*\<0.05. Stata/IC 14.2 was used for all statistical analyses. Additional sensitivity analyses are presented in Figures [S17](#jah33175-sup-0001){ref-type="supplementary-material"} through [S23](#jah33175-sup-0001){ref-type="supplementary-material"}.

Results {#jah33175-sec-0015}
=======

A total of 5831 articles were identified through the search strategy. Following duplicate removal (n=2279), a total of 3552 articles were screened by title and abstract. Of these, 310 articles were assessed by full‐text review. A total of 56 studies were assessed for inclusion in meta‐analyses performed, of which 20 were excluded for the following reasons: 7 studies did not provide HR or RR data; 3 studies provided only effect sizes adjusted for hypoglycemic medication use; 5 studies provided effect sizes which compared diabetes mellitus to non‐diabetes mellitus participants; 1 study provided HR which compared intensively treated to non‐intensively treated cohorts; 1 study had effect size covariate adjustment and stratification limitations; 1 study used a duplicate study population with incomplete HbA~1c~ strata use in effect size calculation; 1 study used a conditional HR that compared stroke and non‐stroke patient cohorts; and 1 study used a pooled cardiovascular disease outcome without stratifying for a stroke outcome. A detailed overview of the study review process is presented in Figure [1](#jah33175-fig-0001){ref-type="fig"}.[22](#jah33175-bib-0022){ref-type="ref"}, [23](#jah33175-bib-0023){ref-type="ref"}, [24](#jah33175-bib-0024){ref-type="ref"}, [25](#jah33175-bib-0025){ref-type="ref"}, [26](#jah33175-bib-0026){ref-type="ref"}, [27](#jah33175-bib-0027){ref-type="ref"}, [28](#jah33175-bib-0028){ref-type="ref"}, [29](#jah33175-bib-0029){ref-type="ref"}, [30](#jah33175-bib-0030){ref-type="ref"}, [31](#jah33175-bib-0031){ref-type="ref"}, [32](#jah33175-bib-0032){ref-type="ref"}, [33](#jah33175-bib-0033){ref-type="ref"}, [34](#jah33175-bib-0034){ref-type="ref"}, [35](#jah33175-bib-0035){ref-type="ref"}, [36](#jah33175-bib-0036){ref-type="ref"}, [37](#jah33175-bib-0037){ref-type="ref"}, [38](#jah33175-bib-0038){ref-type="ref"}, [39](#jah33175-bib-0039){ref-type="ref"}, [40](#jah33175-bib-0040){ref-type="ref"}, [41](#jah33175-bib-0041){ref-type="ref"}

![PRISMA flowchart outlining search strategy implementation and results at each stage. Results presented outline the number of articles identified during each stage of the search strategy. Duplicate removal was performed using the default duplicate removal function within EndNote X7.7.1. Screening by title and abstract was performed independently by 2 researchers using a defined set of inclusion criteria. Full‐text review, including methodological quality assessment, was subsequently performed using defined inclusion criteria. Following this, articles were assessed for meta‐analytical inclusion through consultation between 2 authors using a separate set of inclusion criteria. Articles deemed suitable for meta‐analyses and sensitivity analyses were stratified based on cohort diabetes mellitus status and stroke outcome. Strata that lacked sufficient article number (n\<3 articles) were presented within narrative synthesis only. A total of 29 articles were used in meta‐analyses and sensitivity analyses conducted. The number of studies at each stage (n) is reflected in brackets. AMI indicates acute myocardial infarction; CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL); CVD, cardiovascular disease; ESKD, end‐stage kidney disease; HR, hazard ratio; RR, risk ratio (relative risk); tPA, tissue plasminogen activator.](JAH3-7-e007858-g001){#jah33175-fig-0001}

Of the 36 studies deemed suitable for meta‐analysis, 7 reported recurrent stroke outcome data and were included only in narrative synthesis because of concerns regarding underpowering of meta‐analyses following outcome stratification (Tables [S1--S6](#jah33175-sup-0001){ref-type="supplementary-material"}). A total of 29 studies comprising 532 779 participants were used in meta‐analyses and sensitivity analyses (Figure [1](#jah33175-fig-0001){ref-type="fig"}, [22](#jah33175-bib-0022){ref-type="ref"}, [23](#jah33175-bib-0023){ref-type="ref"}, [24](#jah33175-bib-0024){ref-type="ref"}, [25](#jah33175-bib-0025){ref-type="ref"}, [26](#jah33175-bib-0026){ref-type="ref"}, [27](#jah33175-bib-0027){ref-type="ref"}, [28](#jah33175-bib-0028){ref-type="ref"}, [29](#jah33175-bib-0029){ref-type="ref"}, [30](#jah33175-bib-0030){ref-type="ref"}, [31](#jah33175-bib-0031){ref-type="ref"}, [32](#jah33175-bib-0032){ref-type="ref"}, [33](#jah33175-bib-0033){ref-type="ref"}, [34](#jah33175-bib-0034){ref-type="ref"}, [35](#jah33175-bib-0035){ref-type="ref"}, [36](#jah33175-bib-0036){ref-type="ref"}, [37](#jah33175-bib-0037){ref-type="ref"}, [38](#jah33175-bib-0038){ref-type="ref"}, [39](#jah33175-bib-0039){ref-type="ref"}, [40](#jah33175-bib-0040){ref-type="ref"}, [41](#jah33175-bib-0041){ref-type="ref"}). A narrative summary of baseline participant characteristics within all 36 articles identified for potential inclusion is provided in Tables [S1](#jah33175-sup-0001){ref-type="supplementary-material"} through [S6](#jah33175-sup-0001){ref-type="supplementary-material"}.

First‐Ever Stroke Risk in American Diabetes Association--Defined HbA~1c~ Ranges {#jah33175-sec-0016}
-------------------------------------------------------------------------------

Compared to non--diabetes mellitus range HbA~1c~ (\<5.7%), pre--diabetes mellitus range HbA~1c~ (5.7%--6.5%) was not associated with a significant increased risk of first‐ever stroke (average HR \[95% CI\], 1.19 \[0.87, 1.62\]). In contrast, diabetes mellitus range HbA~1c~ (≥6.5%) was associated with a significant increased risk of first‐ever stroke when compared to non--diabetes mellitus range HbA~1c~ (average HR \[95% CI\], 2.15 \[1.76, 2.63\]).

We identified moderate and low I^2^ statistic values (I^2^=61.3% \[*P*=0.051\] and I^2^=0% \[*P*=0.460\]) for the pre--diabetes mellitus and diabetes mellitus analyses, respectively. We did not find evidence of significant publication bias for either analysis (Figure [S12](#jah33175-sup-0001){ref-type="supplementary-material"}).

Association Between Study‐Quoted 1% HbA~1c~ Increments and First‐Ever Stroke Risk {#jah33175-sec-0017}
---------------------------------------------------------------------------------

Figure [2](#jah33175-fig-0002){ref-type="fig"}, [42](#jah33175-bib-0042){ref-type="ref"}, [43](#jah33175-bib-0043){ref-type="ref"}, [44](#jah33175-bib-0044){ref-type="ref"}, [45](#jah33175-bib-0045){ref-type="ref"}, [46](#jah33175-bib-0046){ref-type="ref"}, [47](#jah33175-bib-0047){ref-type="ref"}, [48](#jah33175-bib-0048){ref-type="ref"}, [49](#jah33175-bib-0049){ref-type="ref"}, [50](#jah33175-bib-0050){ref-type="ref"}, [51](#jah33175-bib-0051){ref-type="ref"}, [52](#jah33175-bib-0052){ref-type="ref"}, [53](#jah33175-bib-0053){ref-type="ref"} summarizes the meta‐analyses assessing the association between study‐quoted rising 1% HbA~1c~ increments and first‐ever stroke risk, stratified by diabetes mellitus status and ischemic stroke subtype. For every 1% HbA~1c~ increment (or equivalent), the average HR (95% CI) for first‐ever stroke risk was 1.12 (0.91, 1.39) in non--diabetes mellitus cohorts and 1.17 (1.09, 1.25) in diabetes mellitus cohorts. When restricted to studies only examining first‐ever ischemic stroke, average HRs (95% CI) were 1.49 (1.32, 1.69) and 1.24 (1.11, 1.39) for non--diabetes mellitus and diabetes mellitus cohorts, respectively.

![Association between study‐quoted rising 1% HbA~1c~ increments and stratified first‐ever stroke risk. Studies presenting hazard ratio (HR) or risk ratio (RR, relative risk) data assessing the association between rising 1% HbA~1c~ increments and first‐ever stroke risk were identified and used to calculate meta‐analytical effect sizes (ES) (95% CI). RR data were treated as equivalent to HR data. Studies using 1 standard deviation (1 SD) HbA~1c~ increments for effect sizes quoted were treated as equivalent to 1% HbA~1c~ increment data. The corresponding HbA~1c~ increments for each standard deviation are as shown in brackets. Studies were stratified based on the diabetes mellitus status of their cohorts and their restriction of first‐ever stroke to an ischemic stroke subtype. The outcome "first‐ever stroke" reflects any stroke subtype. The outcome "first‐ever ischemic stroke" included only studies that specifically restricted their stroke outcome to first‐ever stroke of ischemic subtype. Diabetes cohorts included studies that measured type 1 diabetes mellitus (T1DM), type 2 diabetes (T2DM) or a combination of both (mixed diabetes mellitus cohort). Non--diabetes mellitus cohorts represented studies that used participants with no diabetes mellitus or whose effect size(s) were adjusted for diabetes mellitus. The I^2^ statistic values for each subgroup analysis assessing the percentage of variation across studies that is due to heterogeneity, rather than chance, are presented below each subgroup analysis. A random‐effects model using the inverse‐variance method for weighting was used to generate pooled effect sizes for each subgroup. ES=1.0 indicates no statistically significant association.](JAH3-7-e007858-g002){#jah33175-fig-0002}

The I^2^ statistic value was moderate for the analysis assessing first‐ever stroke risk in patients with diabetes mellitus (I^2^=59.0%, *P*=0.012). Sensitivity analysis identified studies with limited covariate adjustment as the likely source of this moderate I^2^ statistic value (Figure [S6](#jah33175-sup-0001){ref-type="supplementary-material"}). Exclusion of these studies reduced the I^2^ statistic value from moderate to low (reduction from I^2^=59.0% \[*P*=0.012\] to I^2^=41.9% \[*P*=0.111\]) without inducing significant publication bias or altered pooled effect size significance (average HR \[95% CI\], 1.14 \[1.07, 1.20\] prior to exclusion and 1.17 \[1.09, 1.25\] following exclusion). We did not find evidence of significant publication bias in any subgroup analysis (Figures [S13](#jah33175-sup-0001){ref-type="supplementary-material"} and [S14](#jah33175-sup-0001){ref-type="supplementary-material"}).

Association Between Linear Regression Estimated 1% HbA~1c~ Increments and First‐Ever Stroke Risk {#jah33175-sec-0018}
------------------------------------------------------------------------------------------------

For every estimated 1% HbA~1c~ increment (or equivalent), the average HR (95% CI) for first‐ever stroke was 1.17 (1.02, 1.34) and 1.17 (1.01, 1.36) for non--diabetes mellitus and diabetes mellitus cohorts, respectively. When restricted to first‐ever ischemic stroke, average HRs (95% CI) were 1.35 (0.91, 2.02) and 1.32 (1.23, 1.42) for non--diabetes mellitus and diabetes mellitus cohorts, respectively (Figure [S11](#jah33175-sup-0001){ref-type="supplementary-material"}). Inclusion of studies with limited covariate adjustment resulted in a high I^2^ statistic value, as shown in Figure [S7](#jah33175-sup-0001){ref-type="supplementary-material"}. Exclusion of these studies resulted in a reduction of the I^2^ statistic value from high to moderate (reduction from I^2^=89.9% \[*P*\<0.001\] to I^2^=57.7% \[*P*=0.051\]) without inducing statistically significant publication bias (Figures [S15](#jah33175-sup-0001){ref-type="supplementary-material"} and [S16](#jah33175-sup-0001){ref-type="supplementary-material"}) or altering the significance of the pooled effect sizes (average HR \[95% CI\], 1.21 \[1.05, 1.40\] prior to exclusion and 1.17 \[1.01, 1.36\] following exclusion).

Discussion {#jah33175-sec-0019}
==========

We demonstrated a significant association between rising 1% HbA~1c~ increments and first‐ever stroke risk in cohorts with diabetes mellitus. In non--diabetes mellitus cohorts, analysis of estimated 1% HbA~1c~ data revealed a significant relationship with first‐ever stroke, while study‐quoted 1% HbA~1c~ data analyses were significant only for an association with first‐ever ischemic stroke. Analysis of American Diabetes Association diabetes mellitus range HbA~1c~ (≥6.5%) revealed a significant 2.15‐fold increased risk of first‐ever stroke in diabetes mellitus range HbA~1c~ compared to non--diabetes mellitus range HbA~1c~ (\<5.7%).

The absence of a clear association between pre--diabetes mellitus range HbA~1c~ and first‐ever stroke identified is in keeping with the results of a previous meta‐analysis by Huang et al.[54](#jah33175-bib-0054){ref-type="ref"} This study identified a nonsignificant 5% increased risk of stroke associated with pre--diabetes mellitus range HbA~1c~ following meta‐analysis of only 2 studies.[54](#jah33175-bib-0054){ref-type="ref"}

Our study expands upon previous meta‐analyses.[13](#jah33175-bib-0013){ref-type="ref"}, [14](#jah33175-bib-0014){ref-type="ref"} These studies demonstrated a significant association between rising 1% HbA~1c~ increments and stroke risk in patients with type 2 diabetes mellitus (where stroke represented any fatal or nonfatal stroke event) after combining study‐quoted and estimated 1% HbA~1c~ data from a small number of included studies.

Our study addressed these limitations. Our study included 29 studies and studied ischemic stroke specifically. The use of separate meta‐analyses for study‐quoted and linear regression estimated 1% HbA~1c~ data within our meta‐analysis avoids the inherent imputation bias associated with conversion of categorical data into a continuous data set.

Our study suggests the presence of an independent association between chronic hyperglycemia, even in the pre--diabetes mellitus range, and first‐ever stroke risk. The strength of this association was enhanced when restricting stroke outcomes to first‐ever ischemic stroke. This suggests that the inclusion of hemorrhagic and undefined stroke subtypes within the stroke outcome assessed may have blunted the statistical significance of the underlying relationship between hyperglycemia and ischemic stroke. This finding is in keeping with previous research that has suggested that diabetes mellitus is primarily a risk factor for ischemic stroke rather than hemorrhagic stroke,[7](#jah33175-bib-0007){ref-type="ref"} and is supported by pathogenic data that links chronic hyperglycemia and ischemic stroke risk factors.[8](#jah33175-bib-0008){ref-type="ref"}, [9](#jah33175-bib-0009){ref-type="ref"}, [10](#jah33175-bib-0010){ref-type="ref"}, [11](#jah33175-bib-0011){ref-type="ref"}

The DCCT/EDIC (Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study) demonstrated a statistically significant risk reduction in macrovascular complication risk in participants managed initially with intensive glycemic control measures following 17 years of follow‐up of a type 1 diabetes mellitus population.[5](#jah33175-bib-0005){ref-type="ref"}, [55](#jah33175-bib-0055){ref-type="ref"} Similarly, the UKPDS (United Kingdom Prospective Diabetes Study) follow‐up study[6](#jah33175-bib-0006){ref-type="ref"} demonstrated that intensive glycemic control in patients with type 2 diabetes mellitus led to fewer macrovascular complications after prolonged follow‐up, suggesting a metabolic memory effect for earlier intensive control.

Despite this, several randomized controlled trials including VADT (Veterans Affairs Diabetes Trial),[56](#jah33175-bib-0056){ref-type="ref"} ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation)[57](#jah33175-bib-0057){ref-type="ref"} and ACCORD (Action to Control Cardiovascular Risk in Diabetes)[58](#jah33175-bib-0058){ref-type="ref"} have refuted the presence of a statistically significant macrovascular complication risk reduction offered by intensified glycemic control, in the context of type 2 diabetes mellitus management. Common limitations within these randomized controlled trials that may explain the incongruence of their results with DCCT/EDIC and UKPDS include; the comparatively short follow‐up intervals used, competing risk confounding associated with the older age of participants used, the inclusion of participants with poorly controlled diabetes mellitus, and, importantly, the inclusion of participants with preexisting cardiovascular disease (may be at heightened risk of hypoglycemia with insulin and sulfonylurea therapy). Newer agents reduce cardiovascular outcomes without major changes in HbA~1c~ or improved glycemic control, but these may act through other pathways and do not deter from the finding that pre--diabetes mellitus, as determined by HbA~1c~ level, appears associated with incident ischemic stroke.[59](#jah33175-bib-0059){ref-type="ref"} This is evident within 2 recent glucagon‐like peptide‐1 trials that demonstrated significant reductions in a combined cardiovascular outcome of cardiovascular death, nonfatal acute myocardial infarction, or nonfatal stroke through their use in type 2 diabetes mellitus populations with high cardiovascular disease risk.[60](#jah33175-bib-0060){ref-type="ref"}, [61](#jah33175-bib-0061){ref-type="ref"}

Several measures were implemented within our study with the intention of reducing the magnitude of interstudy heterogeneity. We attempted to reduce heterogeneity by implementing an extensive set of inclusion and exclusion criteria that were designed to reduce common sources of heterogeneity and bias, including but not limited to; variability in study design, variability in effect measures used, insufficient follow‐up time, and insufficient covariate adjustment. Given the implicit heterogeneity of observational study designs, a random‐effects model was used in all analyses performed. The use of subgroup meta‐analyses, stratified for key outcome parameters including stroke subtype (first‐ever ischemic stroke versus first‐ever stroke) and cohort diabetes mellitus status (diabetes mellitus versus non--diabetes mellitus cohorts), further aimed to reduce outcome measure related heterogeneity.

Of the subgroup meta‐analyses focusing on the association between rising 1% HbA~1c~ increments and first‐ever stroke risk, only 2 demonstrated I^2^ values exceeding 25%, thereby indicating a very good level of heterogeneity control through our study design. Sensitivity analyses performed in Figures [S6](#jah33175-sup-0001){ref-type="supplementary-material"} and [S7](#jah33175-sup-0001){ref-type="supplementary-material"} demonstrated reductions in the magnitude of heterogeneity detected from moderate to low and high to moderate, respectively, following exclusion of studies with limited covariate adjustment. Given this result, it is a reasonable assertion that differences in the types and number of covariates adjusted for within individual studies is a likely major contributor to the statistical heterogeneity measured. This is not surprising when considering that many of these variables, including; age, sex, hypertension, smoking status, cholesterol level, and history of cardiovascular disease, are independent risk factors for the development of vascular disease including stroke.

A further potential reason for the statistical heterogeneity measured relates to the unavoidable differences in study definitions for key parameters of diabetes mellitus status and stroke. Decisions made relating to the treatment of studies whose results were statistically adjusted for past history of diabetes mellitus and stroke, and the acceptance of study‐quoted diabetes mellitus and stroke outcome descriptors may also have contributed to the level of statistical heterogeneity detected but were unavoidable given the inherent variability in outcome definitions present within observational study designs.

Our study has limitations. We restricted our studies to those reporting only RR and HR data. The lack of a common, standardized definition for diabetes mellitus across all the studies could result in assessment bias. Likewise, the inclusion of studies with different stroke outcome classification systems is suboptimal given the inherent differences within the classification systems used. The use of a linear regression model to ≈1% HbA~1c~ effect size data from categorical HbA~1c~ data can provide only an approximation of this relationship and could not be combined with quoted data. The variability in covariate adjustment performed (types and number of covariates adjusted for) within the source studies included in our analyses imposed limitations on our ability to examine the independent effects of individual covariate adjustment on the statistical heterogeneity calculated using the I^2^ statistic. Likewise, the limited number of studies (n\<10) within each subgroup meta‐analysis performed precluded the implementation of meta‐regression techniques.

Although a comprehensive search strategy assessing multiple literary databases was performed, we may not have identified all relevant literature on this topic. We also did not include studies addressing this topic in languages other than English. We did not have access to individual patient data that would have permitted more detailed analyses. Our data are, however, in line with an individual patient data meta‐analysis that assessed the risk of a composite outcome of stroke and myocardial infarction with varying levels of HbA~1c~.[62](#jah33175-bib-0062){ref-type="ref"} That study did not report on stroke outcomes separately but was able to identify an increased risk of acute myocardial infarction/stroke in patients with low levels of HbA~1c~.[62](#jah33175-bib-0062){ref-type="ref"} Our methodology was not able to identify such a J‐shaped relationship. The limited number of articles within each subgroup analysis prevented use of formal meta‐regression and analysis of HbA~1c~ as a risk factor for recurrent stroke.

Conclusions {#jah33175-sec-0020}
===========

In summary, our study suggests that both continuous and categorical elevations in HbA~1c~ are associated with increased first‐ever ischemic stroke risk, irrespective of diabetes mellitus status. Prevention of macrovascular complications like stroke may need to start at lower HbA~1c~ thresholds. Further interventional studies are needed to explore the effectiveness of more intensive glycemic management within primary and secondary stroke prevention, in pre--diabetes mellitus and diabetes mellitus cohorts.
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